Sector Expert: Jim Molloy

Laidlaw & Company

Image: Jim Molloy

Jim Molloy brings over 15 years of sellside experience to Laidlaw, having covered specialty pharmaceuticals and biotechnology for a diverse group of Wall Street investment banks. Prior to Laidlaw, Molloy was a managing director at Summer Street Research Partners and Janney Montgomery Scott; prior to that he was a senior analyst at ThinkEquity Partners, Caris & Company, Oppenheimer, and Leerink Swann & Company. Molloy has been ranked by Forbes/Starmine for earnings accuracy. He received his master’s degree in business administration from the FW Olin Graduate School of Business at Babson College, and his bacherlor’s degree from the University of Colorado, Boulder.



Recent Interviews

From Acorns Mighty Biotech Trees Can Grow: Laidlaw's Jim Molloy (3/16/16)
moneyinbeaker630

After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug developers to begin acquiring smaller biotechs trading at depressed market valuations. In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices. In this interview with The Life Sciences Report, Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios.

Recent Quotes

"We continue to believe that, should Posimir read out positively and DUR-928 get out of Phase 1 trials, DRRX is an undervalued story here."

— Jim Molloy, Laidlaw & Company (3/15/17)
more >

"DRRX announced encouraging preliminary data last night in their Phase 1b chronic NASH study."

— Jim Molloy, Laidlaw & Company (11/1/16)
more >

"DRRX's DUR-928 is still expected to read out Phase 1 data in 4Q16 for both liver (NASH) and kidney, and Posimur remains on track for 4Q17 Phase 3 data on post-surgical pain relief."

— Jim Molloy, Laidlaw & Company (9/30/16)
more >

"DRRX enters what could be one of the most productive second halves of the year in the company's history."

— Jim Molloy, Laidlaw & Company (8/29/16)
more >

"DRRX has a deep pipeline with multiple near-term catalysts that could drive shareholder value."

— Jim Molloy, Laidlaw & Company (8/2/16)
more >

"The winds are blowing in favor of DRRX's Remoxy this go-around."

The Life Sciences Report Interview with Jim Molloy (3/16/16)
more >

"We are initiating coverage on CTRV with a Buy rating."

— Jim Molloy, Laidlaw & Company (11/4/15)
more >

"DRRX has begun recruiting patients for the pivotal Phase 3 trial for Posimir."

— Jim Molloy, Laidlaw & Company (11/3/15)
more >



Due to permission requirements, not all quotes are shown.